The Securities and Exchange Commission has not necessarily
reviewed the information in this filing and has not determined
if it is accurate and complete.
| |||||||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| 10X GENOMICS INC | CL A COM | 88025U109 | 8,351,756 | 217,834 | SH | SOLE | 0 | 0 | 217,834 | ||
| BEAM THERAPEUTICS INC | COM | 07373V105 | 155,771,929 | 4,540,132 | SH | SOLE | 0 | 0 | 4,540,132 | ||
| BOUNDLESS BIO INC | COM | 10170A100 | 6,735,238 | 2,694,095 | SH | SOLE | 0 | 0 | 2,694,095 | ||
| ERASCA INC | COM | 29479A108 | 129,917,324 | 7,091,557 | SH | SOLE | 0 | 0 | 7,091,557 | ||
| GENERATE BIOMEDICINES INC | COM SHS | 370920100 | 32,802,467 | 1,944,426 | SH | SOLE | 0 | 0 | 1,944,426 | ||
| GOSSAMER BIO INC | COM | 38341P102 | 1,326,004 | 8,055,916 | SH | SOLE | 0 | 0 | 8,055,916 | ||
| LYELL IMMUNOPHARMA INC | COM NEW | 55083R203 | 45,525,211 | 3,247,162 | SH | SOLE | 0 | 0 | 3,247,162 | ||
| MAZE THERAPEUTICS INC | COM | 578784100 | 122,983,582 | 4,120,053 | SH | SOLE | 0 | 0 | 4,120,053 | ||
| PARABILIS MEDICINES INC | COM | 698955101 | 175,517,789 | 6,412,780 | SH | SOLE | 0 | 0 | 6,412,780 | ||
| RAPPORT THERAPEUTICS INC | COM | 75383L102 | 155,376,512 | 3,728,738 | SH | SOLE | 0 | 0 | 3,728,738 | ||
| SEAPORT THERAPEUTICS INC | COMMON STOCK | 81221K108 | 136,600,437 | 6,294,951 | SH | SOLE | 0 | 0 | 6,294,951 | ||
| VIR BIOTECHNOLOGY INC | COM | 92764N102 | 129,353,521 | 12,694,163 | SH | SOLE | 0 | 0 | 12,694,163 | ||